Synthetic securitisation
Synthetic securitisation is the product; Significant Risk Transfer (SRT) is the regulatory outcome that a well-structured synthetic securitisation may achieve under Articles 244–249 CRR. The two terms are frequently used interchangeably in market shorthand, but the distinction matters for structuring, supervisory dialogue and disclosure.
On this page
What a synthetic securitisation is
In a synthetic securitisation the originator (typically a bank) keeps legal title to a reference loan portfolio but transfers a defined tranche of credit risk — usually a first-loss or mezzanine layer — to third-party investors via credit-linked notes, a funded or unfunded credit derivative, or a guarantee. The transfer is documented in a credit-protection agreement (the “collateralisation agreement” in the Securitisation Regulation's terminology), under which the originator pays a protection premium and the protection provider undertakes to make a compensation payment on specified credit events.
The economic attraction is that the originator keeps the customer, the origination capability and the servicing income; only the credit risk (and, with it, the regulatory capital charge) is passed on. In a traditional (“true sale”) securitisation — see CMBS for the main CRE example — the assets themselves leave the balance sheet. In a synthetic securitisation they stay put.
Synthetic securitisation vs. SRT — why the distinction matters
The synthetic securitisation is the transaction. Significant Risk Transfer (SRT) is the regulatory result the originator is trying to achieve through that transaction: the recognition, under Articles 244–245 CRR, that enough credit risk has been transferred to third parties for the originator to stop holding regulatory capital against the underlying reference portfolio and to hold capital instead only against its retained securitisation position (typically the senior tranche and the 5% minimum risk retention).
Three consequences follow from the distinction:
• A synthetic securitisation is not automatically an SRT transaction. A synthetic securitisation delivers SRT only if the quantitative gates in Article 244(2) / 245(2) CRR and the qualitative requirements in Article 244(4) / 245(4) CRR are met and are accepted by the competent supervisor. A mis-structured synthetic securitisation may move economic risk without obtaining regulatory SRT — and therefore without delivering capital relief.
• A traditional securitisation can also achieve SRT. Article 244 CRR governs SRT for traditional securitisations; Article 245 CRR governs SRT for synthetic securitisations. In European CRE, synthetic structures dominate because the bank typically wants to keep the loan relationship, but the SRT concept is not synthetic-specific.
• SRT status has to be maintained. It is tested at origination and re-tested by the supervisor if deal parameters change (replenishment, concentration, valuations). A synthetic securitisation that qualified as an SRT on day one can lose that recognition in-life.
The SRT page sets out the regulatory requirements in detail. This page concentrates on the synthetic-securitisation product itself.
Market snapshot 2025 / 2026
The USD 41 bn figure captures the volume of synthetic securitisation transactions structured to achieve SRT. Market commentary typically refers to this as “SRT issuance” — strictly, it is the issuance of synthetic securitisations aimed at, and in principle delivering, SRT. Q4 2025 alone exceeded full-year pre-2022 volumes. Banks have securitised only c. 5% of their corporate loan books and c. 3% of total portfolios — on Crescent Capital's estimates, a 5-percentage-point utilisation rate increase could add USD 75 bn of annual issuance.
In CRE specifically, 2025 was the first breakout year. CRE still represents only c. 5% of the asset mix (corporates 58%, SME 14%, consumer 8%, fund finance 6%, project finance / infra 5%) — but the trajectory is clear. 36% of European bank respondents in a 2026 industry survey said they already use or are actively exploring synthetic securitisation; 65% expect it to become a significantly important tool for the European CRE lending market.
Regulatory framework
Core instruments. CRR Articles 244–249 (capital treatment and SRT recognition); Regulation (EU) 2017/2402 (Securitisation Regulation), in particular Articles 6 (risk retention), 7 (transparency), 26a–26e (STS criteria for balance-sheet synthetic securitisations) and 27 (STS notification); EBA Guidelines on SRT assessment (2024 final, effective 2025); ECB SSM public communications on genuine-risk-transfer (GRT); PRA supervisory statements.
Balance-sheet synthetic STS. Since the Capital Markets Recovery Package (February 2021), synthetic securitisations of balance-sheet exposures can be designated STS under Articles 26a–26e of the Securitisation Regulation. The STS label unlocks the Article 270 CRR preferential risk-weight treatment for the retained senior tranche, subject to stringent requirements on collateral, the collateralisation agreement and the credit-protection instrument.
Three regulator gates for SRT. (i) Is enough risk actually transferred; (ii) is the pricing / tranche sizing commensurate; (iii) is the structure robust (clean-up calls, amortisation, replenishment, early-termination). Each gate is tested at origination and re-tested by the supervisor if deal parameters change. See the dedicated SRT page for the detail.
Investor universe. Pemberton, AXA IM Alts, Ares, KKR, Cheyne, PGGM, Chorus Capital, Christofferson Robb, plus a growing list of insurance / pension mandates. The UK PRA and ECB have publicly warned about “negative feedback loops” where the risk stays within the wider banking system — a governance point to watch.
CRE-specific considerations
Granularity. Classical SRT logic depends on pool diversification. CRE is lumpy. The 2025/26 CRE breakthrough in synthetic securitisation has come from pools that look more like traditional securitisation pools (≥30 names, geographic spread, sector spread) rather than three-loan chunky decks. Supervisors are comfortable with the more granular structure; the three-loan structure raises immediate GRT-test concerns.
Valuation volatility. Tranche thickness and attachment points are far more sensitive to valuation swings than in corporate synthetic securitisation. Reference-pool LTV cut-offs and MtM triggers are heavily negotiated. Where the reference pool is shared with a CMBS warehouse, the two valuation frameworks need to reconcile.
Interaction with back leverage. Investors in the protection tranches increasingly part-fund their position with back leverage from other banks — creating the circular exposure that regulators have flagged. The legal documentation needs to anticipate bifurcated funding and collateral flows, particularly on enforcement.
Accounting / derecognition. A synthetic securitisation only releases capital if the accounting treatment follows. IFRS 9 derecognition and the SPPI test must align with the regulatory SRT position — mis-alignments are a classic source of execution risk and a recurring source of supervisory questioning.
Last reviewed: 20 April 2026. Data sources: Resources. For the regulatory-law detail on Significant Risk Transfer see the separate SRT page; for short definitions of the technical terms used on this page see the Glossary.